ERBB2 and breast cancer: To our best knowledge, the cost per patient of pertuzumab in neoadjuvant context was not yet calculated using real-world patient level data, thus this research aims to estimate the average direct medical costs per patient by adding pertuzumab in the clinical practice to the NeoT of HER2-positive BC patients, as well as to calculate the weight of pertuzumab in the overall costs.